Orexo AB
http://www.orexo.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Orexo AB
What’s Next? Five Things To Look Out For In August
Second-quarter earnings results from two of the Big Three – Teva and Mylan – hold much of the intrigue in August, while more competition in the nascent Avastin biosimilar market could materialize in Europe.
Deal Watch: Roche And Vividion Will Investigate E3 Ligases In Cancer, Immunology
Also, news on transactions involving Neurocrine/Idorsia, Neurotrope/Metuchen, jCyte/Santen, PTC/Censa, Hoth/Chelexa, Skyhawk/Merck & Co., Orexo/Gaia, Karo/J&J, MaxCyte/Caribou, Mediolanum/ElsaLys, Avectas/ONK
Orexo Files Alcohol Abuse Digital Therapy With US FDA
The Swedish firm is taking a multifaceted approach to treating substance use disorders such as alcohol addiction, by offering both medication and psycho-social support.
Deal Watch: Themis Leverages Measles Vector Platform In Collaboration With Merck & Co.
In its first big pharma deal, Austrian biotech will develop experimental vaccines for Merck against an undisclosed target. Innovent licenses Chinese rights to Lilly diabetes candidate, while Novartis gets option to Iconic’s preclinical ophthalmology program.
Company Information
- Industry
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Biolipox AB
- PharmaKodex Ltd.